Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2021. Start Trial.
Date Value
September 30, 2026 37.10M
June 30, 2026 40.11M
March 31, 2026 35.41M
December 31, 2025 31.86M
September 30, 2025 22.53M
June 30, 2025 30.64M
March 31, 2025 24.19M
December 31, 2024 22.70M
September 30, 2024 25.48M
June 30, 2024 13.14M
March 31, 2024 15.22M
December 31, 2023 17.78M
Date Value
September 30, 2023 14.63M
June 30, 2023 12.22M
March 31, 2023 10.77M
December 31, 2022 7.591M
September 30, 2022 6.740M
June 30, 2022 5.402M
March 31, 2022 4.718M
December 31, 2021 3.805M
September 30, 2021 2.980M
June 30, 2021 2.607M
March 31, 2021 1.485M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
EyePoint, Inc. 296.65M
Neumora Therapeutics, Inc. 135.16M
LENZ Therapeutics, Inc. 0.00
ANI Pharmaceuticals, Inc. 50.60M
Corcept Therapeutics, Inc. 241.72M